Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) a clinical stage biopharmaceutical firm advancing next generation targeted treatments for the cancer treatment, reported an update on the efficacy and safety of RX-3117 in an underway Phase IIa clinical study in metastatic pancreatic cancer at the ASCO 2017 Gastrointestinal Cancer Symposium in California.
The expert view
Ely Benaim, M.D., the Chief Medical Officer for Rexahn, said that the report on progression free survival in subjects with metastatic pancreatic cancer treated with RX-3117 is encouraging with 20% of subjects showing progression free survival of over 5.6 months. A majority of the subjects registered in the study have already been unsuccessful in 3 or more previous cancer treatments. Current options for these subjects are usually confined to painkilling or best supportive care; there are no medications accepted for metastatic pancreatic cancer subjects that have failed 2 or more prior treatments.
Peter D. Suzdak, Ph.D., the CEO of Rexahn, reported that the company’s development plan for ‘RX-3117’ in pancreatic cancer is to persist to advance ‘RX-3117’ as monotherapy for subjects with metastatic disease who failed two or more previous therapies, and also alongside, to advance ‘RX-3117’ in combination with Abraxane® for people with metastatic pancreatic cancer who didn’t get any prior chemotherapy therapy.
Since there are no medications approved for subjects who have not responded to two or more treatments, there may be a quicker regulatory pathway going for this patient population, supposing company continue to witness efficacy with ‘RX-3117.’ Additionally, during the first quarter, the company intends to commence a Phase IIa clinical study of ‘RX-3117’ in combination with Abraxane® in people recently diagnosed with metastatic pancreatic cancer. They anticipate the preliminary data from this study will be available in 2018.
The updated efficacy report for RX-3117 from an underway Phase IIa clinical study in metastatic pancreatic cancer was demonstrated last week in a poster presentation.